NEW YORK (GenomeWeb News) – Protea Biosciences has licensed technology from Johns Hopkins University that it plans to use to develop tools for improving treatment of myocardial ischemia, the company said today.

The company has licensed technology developed in the lab of Hopkins researcher Jennifer Van Eyk that has been used to identify proteins bound to human serum albumin that are associated with cardiovascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.